Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibition
K. Jamal, A. Galbiati, J. Armenia, G. Illuzzi, J. Hall, S. Bentouati, D. Barrell, M. Ahdesmäki, Functional Genomics Centre, M. J. O'Connor, E. Leo, J. V. Forment
The paper identifies 110 genes linked to PARP inhibitor sensitivity through CRISPR screens and tumor data analysis, highlighting XRCC3 as a potential biomarker for prostate cancer.
bioRxiv · Jul 29, 2022Cancer Biology